NICE Archives -

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to

MHRA, NHS England make available new prostate cancer treatment

https://pharmaphorum.com/news/mhra-nhs-england-make-available-new-prostate-cancer-treatment/

Market Access/ News/ News/ News/ Patients

NICE rejects five COVID drugs and backs three on price, efficacy data

Phil Taylor coronavirus, COVID-19, Evusheld, HEOR, Lagevrio, NHS, NICE, Olumiant, Paxlovid, Ronapreve, Veklury, xevudy 0 Comment

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid,

NICE rejects five COVID drugs and backs three on price, efficacy data

https://pharmaphorum.com/news/nice-rejects-five-covid-drugs-and-backs-three-on-price-efficacy-data/

Cancer/ News/ News/ Oncology

Ipsen’s Cabometyx recommended by NICE for previously treated HCC

Nicole Raleigh British Liver Trust, Cabometyx, cabozantinib, HCC, Ipsen, Liver cancer, NICE, UCL Cancer Institute 0 Comment

French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care Excellence (NICE)

Ipsen’s Cabometyx recommended by NICE for previously treated HCC

https://pharmaphorum.com/news/ipsens-cabometyx-recommended-by-nice-for-previously-treated-hcc/

News/ News/ News/ Oncology

NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer

Eloise McLennan cancer immunotherapy, Keytruda, Merck, MSD UK, NICE, Oncology, pharma news, triple negative breast cancer 0 Comment

For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy

NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer

https://pharmaphorum.com/news/nice-backs-use-of-msds-keytruda-for-triple-negative-breast-cancer/

Digital/ Market Access/ News/ News/ News/ News/ Patients

NICE backs digital CBT apps for youngsters with anxiety

Phil Taylor anxiety, digital, digital health, HEOR, NHS, NICE, paediatrics 0 Comment

Draft guidance in the UK has provisionally recommended that digital cognitive behavioural therapy (CBT) apps can be used

NICE backs digital CBT apps for youngsters with anxiety

https://pharmaphorum.com/news/nice-backs-digital-cbt-apps-for-youngsters-with-anxiety/

IQVIA Webinar on Innovative Medicines Fund

Market Access/ Slider in home page/ Views & Analysis/ Webinars/ Webinars in home page/ Webinars On demand

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

mike.hammerton@pharmaphorum.com Innovative Medicines Fund, IQVIA, NHSE, NICE 0 Comment

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

https://pharmaphorum.com/webinars/innovative-medicines-fund-and-the-opportunity-for-icss-to-mobilise-nice-approvals/

Market Access/ News/ News

NICE says yes to Grifols’ Tavlesse for rare blood disorder ITP

Phil Taylor Grifols, HEOR, immune thrombocytopenia, NHS, NICE, rare disease, Tavlesse 0 Comment

Patients across the UK with chronic immune thrombocytopenia (ITP) now have another treatment option, after NICE backed use

NICE says yes to Grifols’ Tavlesse for rare blood disorder ITP

https://pharmaphorum.com/news/nice-says-yes-to-grifols-tavlesse-for-rare-blood-disorder-itp/

Why research into the mental health impact of a rare disease diagnosis is long overdue

Digital/ News/ News/ News/ Patients

Wellcome funds work on regulating digital mental health tools

Phil Taylor digital, digital health, medical device, mental health, MHRA, NICE, regulatory, Wellcome 0 Comment

An explosion of digital mental health tools being offered for sale has presented regulators with a problem –

Wellcome funds work on regulating digital mental health tools

https://pharmaphorum.com/news/wellcome-funds-work-on-regulating-digital-mental-health-tools/

Market Access/ News/ News/ Press Releases

Translarna not approved by NICE for DMD on NHS

Nicole Raleigh ataluren, DMD, Duchenne muscular dystrophy, NICE, Translarna 0 Comment

In draft guidance published on Friday, it emerged NICE does not recommend PTC Therapeutics’ Translarna (ataluren) for the

Translarna not approved by NICE for DMD on NHS

https://pharmaphorum.com/news/translarna-not-approved-by-nice-for-dmd-on-nhs/

Trending

NICE

Login